Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

MLA

Enrique Velez-Garcia, et al. “Long-Term Follow-up of Three Randomized Trials Comparing Idarubicin and Daunorubicin as Induction Therapies for Patients with Untreated Acute Myeloid Leukemia.” Cancer, vol. 80, Dec. 1997, pp. 2181–85. EBSCOhost, https://doi.org/10.1002/(sici)1097-0142(19971201)80:11+<2181::aid-cncr3>3.0.co;2-l.

APA

Enrique Velez-Garcia, Peter Wiernik, Ellin Berman, Ralph Vogler, Alfred A. Bartolucci, & Fredrick S. Whaley. (1997). Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer, 80, 2181–2185. https://doi.org/10.1002/(sici)1097-0142(19971201)80:11+<2181::aid-cncr3>3.0.co;2-l

Chicago

Enrique Velez-Garcia, Peter Wiernik, Ellin Berman, Ralph Vogler, Alfred A. Bartolucci, and Fredrick S. Whaley. 1997. “Long-Term Follow-up of Three Randomized Trials Comparing Idarubicin and Daunorubicin as Induction Therapies for Patients with Untreated Acute Myeloid Leukemia.” Cancer 80 (December): 2181–85. doi:10.1002/(sici)1097-0142(19971201)80:11+<2181::aid-cncr3>3.0.co;2-l.